Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 61


New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval.

Zannad F, Rossignol P, Stough WG, Epstein M, Alonso Garcia Mde L, Bakris GL, Butler J, Kosiborod M, Berman L, Mebazaa A, Rasmussen HS, Ruilope LM, Stockbridge N, Thompson A, Wittes J, Pitt B.

Int J Cardiol. 2016 Aug 1;216:46-51. doi: 10.1016/j.ijcard.2016.04.127. Review.


Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.

Anker SD, Kosiborod M, Zannad F, Piña IL, McCullough PA, Filippatos G, van der Meer P, Ponikowski P, Rasmussen HS, Lavin PT, Singh B, Yang A, Deedwania P.

Eur J Heart Fail. 2015 Oct;17(10):1050-6. doi: 10.1002/ejhf.300.


New agents for hyperkalemia.

Packham DK, Rasmussen HS, Singh B.

N Engl J Med. 2015 Apr 16;372(16):1571-2. No abstract available.


The effect of increased classroom ventilation rate indicated by reduced CO2 concentration on the performance of schoolwork by children.

Petersen S, Jensen KL, Pedersen AL, Rasmussen HS.

Indoor Air. 2016 Jun;26(3):366-79. doi: 10.1111/ina.12210.


Characterization of structure and function of ZS-9, a K+ selective ion trap.

Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS.

PLoS One. 2014 Dec 22;9(12):e114686. doi: 10.1371/journal.pone.0114686.


Sodium zirconium cyclosilicate in hyperkalemia.

Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B.

N Engl J Med. 2015 Jan 15;372(3):222-31. doi: 10.1056/NEJMoa1411487.


Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.

Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B.

JAMA. 2014 Dec 3;312(21):2223-33. doi: 10.1001/jama.2014.15688. Erratum in: JAMA. 2015 Feb 3;313(5):526. Dosage error in text.


Quality of life and pruritus in patients with severe sepsis resuscitated with hydroxyethyl starch long-term follow-up of a randomised trial.

Wittbrodt P, Haase N, Butowska D, Winding R, Poulsen JB, Perner A; 6S trial group.; Scandinavian Critical Care Trials Group..

Crit Care. 2013 Feb 25;17(2):R58. doi: 10.1186/cc12586.


Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis.

Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J; 6S Trial Group.; Scandinavian Critical Care Trials Group..

N Engl J Med. 2012 Jul 12;367(2):124-34. doi: 10.1056/NEJMoa1204242. Erratum in: N Engl J Med. 2012 Aug 2;367(5):481.


A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease.

Fuchs S, Dib N, Cohen BM, Okubagzi P, Diethrich EB, Campbell A, Macko J, Kessler PD, Rasmussen HS, Epstein SE, Kornowski R.

Catheter Cardiovasc Interv. 2006 Sep;68(3):372-8.


Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.

Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS.

Gene Ther. 2006 Nov;13(21):1503-11.


A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities.

Mundt AJ, Vijayakumar S, Nemunaitis J, Sandler A, Schwartz H, Hanna N, Peabody T, Senzer N, Chu K, Rasmussen CS, Kessler PD, Rasmussen HS, Warso M, Kufe DW, Gupta TD, Weichselbaum RR.

Clin Cancer Res. 2004 Sep 1;10(17):5747-53.


VEGF gene therapy for coronary artery disease and peripheral vascular disease.

Rasmussen HS, Rasmussen CS, Macko J.

Cardiovasc Radiat Med. 2002 Apr-Jun;3(2):114-7. Review.


Angiogenic gene therapy strategies for the treatment of cardiovascular disease.

Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G.

Curr Opin Mol Ther. 2002 Oct;4(5):476-81. Review.


Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy.

Weichselbaum RR, Kufe DW, Hellman S, Rasmussen HS, King CR, Fischer PH, Mauceri HJ.

Lancet Oncol. 2002 Nov;3(11):665-71. Review.


Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions.

Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C.

Hum Gene Ther. 2002 Jan 1;13(1):65-100.


Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions.

Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG.

Hum Gene Ther. 2002 Jan 1;13(1):15-63.


Looking into anti-angiogenic gene therapies for disorders of the eye.

Rasmussen HS, Rasmussen CS, Durham RG, King CR, Wei L.

Drug Discov Today. 2001 Nov 15;6(22):1171-1175.

Items per page

Supplemental Content

Loading ...
Support Center